189,000 Shares in Bausch Health Companies Inc. (NYSE:BHC) Bought by Intact Investment Management Inc.

Intact Investment Management Inc. acquired a new position in Bausch Health Companies Inc. (NYSE:BHC - Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 189,000 shares of the company's stock, valued at approximately $1,543,000. Intact Investment Management Inc. owned about 0.05% of Bausch Health Companies at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the company. Van ECK Associates Corp grew its holdings in shares of Bausch Health Companies by 13.5% during the third quarter. Van ECK Associates Corp now owns 343,268 shares of the company's stock worth $2,770,000 after buying an additional 40,797 shares in the last quarter. International Assets Investment Management LLC purchased a new position in shares of Bausch Health Companies in the third quarter worth about $1,910,000. Creative Planning boosted its position in Bausch Health Companies by 16.9% during the third quarter. Creative Planning now owns 55,351 shares of the company's stock worth $452,000 after acquiring an additional 7,995 shares during the last quarter. Clearline Capital LP purchased a new stake in Bausch Health Companies during the 2nd quarter valued at about $6,881,000. Finally, Mackenzie Financial Corp raised its holdings in Bausch Health Companies by 111.0% in the 2nd quarter. Mackenzie Financial Corp now owns 2,381,888 shares of the company's stock valued at $16,612,000 after acquiring an additional 1,252,834 shares during the last quarter. 78.65% of the stock is currently owned by hedge funds and other institutional investors.

Bausch Health Companies Stock Performance

Shares of Bausch Health Companies stock traded up $0.43 on Tuesday, reaching $9.69. The company had a trading volume of 2,334,326 shares, compared to its average volume of 2,944,378. The firm's 50 day moving average price is $7.62 and its two-hundred day moving average price is $7.05. Bausch Health Companies Inc. has a 52-week low of $3.96 and a 52-week high of $11.46. The firm has a market cap of $3.56 billion, a PE ratio of -19.94 and a beta of 0.74.

Bausch Health Companies (NYSE:BHC - Get Free Report) last released its quarterly earnings results on Wednesday, October 30th. The company reported $1.12 EPS for the quarter, topping analysts' consensus estimates of $1.02 by $0.10. Bausch Health Companies had a negative return on equity of 755.86% and a negative net margin of 1.88%. The company had revenue of $2.51 billion for the quarter, compared to analysts' expectations of $2.42 billion. During the same period in the prior year, the firm earned $1.03 earnings per share. The firm's revenue was up 12.2% compared to the same quarter last year. As a group, sell-side analysts predict that Bausch Health Companies Inc. will post 3.73 EPS for the current year.

Insider Activity at Bausch Health Companies

In related news, EVP Seana Carson sold 13,370 shares of Bausch Health Companies stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $6.21, for a total value of $83,027.70. Following the completion of the transaction, the executive vice president now owns 435,198 shares in the company, valued at approximately $2,702,579.58. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 8.12% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

BHC has been the subject of a number of analyst reports. StockNews.com upgraded Bausch Health Companies from a "hold" rating to a "buy" rating in a research report on Friday, October 25th. Evercore ISI upgraded Bausch Health Companies to a "hold" rating in a report on Tuesday, October 15th. Jefferies Financial Group reduced their price target on Bausch Health Companies from $13.00 to $9.00 and set a "buy" rating on the stock in a report on Wednesday, August 7th. Raymond James assumed coverage on shares of Bausch Health Companies in a research note on Wednesday, July 10th. They set a "market perform" rating and a $8.00 target price on the stock. Finally, Scotiabank dropped their price target on shares of Bausch Health Companies from $10.00 to $8.50 and set a "sector perform" rating for the company in a research note on Friday, August 2nd. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat, Bausch Health Companies presently has a consensus rating of "Hold" and a consensus price target of $7.75.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.